A FOURTEEN-WEEK PLACEBO-CONTROLLED DOSE-RESPONSE EFFICACY AND SAFETY STUDY OF NS 2330 IN EARLY PARKINSON'S DISEASE PATIENTS (STUDY FOR PROOF OF CONCEPT IN EARLY PARKINSON'S DISEASE OF A TRIPLE REUPTAKE INHIBITOR, NS 2330 / SCEPTRE):